Atyr’s Covid-19 benefit claims raise questions

If Atyr Pharma had hoped for a big share price boost on the back of claims of activity in a study of its lead project, ATYR1923, in Covid-19 it will have been disappointed, as its stock opened up just 1% this morning. And quite right: scrutiny of the data, revealed after market close yesterday, raises doubts about whether the neuropilin-2 modulator conferred any real benefit.